Crescent Biopharma

Crescent Biopharma is a biotechnology company focused on developing innovative cancer therapies aimed at transforming the treatment of solid tumors. The company operates in the biopharmaceutical industry, targeting healthcare providers and cancer patients as its primary clients. Crescent Biopharma's business model revolves around the research and development of novel biologics, which are drugs derived from living organisms, to offer potentially best-in-class therapies. These therapies are designed to improve patient outcomes and provide new treatment options for those affected by cancer. The company generates revenue through the commercialization of its drug pipeline, which originated from Paragon Therapeutics, a biotechnology company founded by Fairmount. Crescent Biopharma is the fifth company launched to advance assets discovered at Paragon, highlighting its strategic focus on leveraging cutting-edge research to address unmet medical needs in oncology. The company is committed to maintaining high standards of data protection and privacy, ensuring that any personally identifiable information collected is safeguarded and not sold or rented to third parties.

Keywords: cancer therapies, solid tumors, biologics, biotechnology, oncology, drug development, Paragon Therapeutics, Fairmount, healthcare, innovation.